Reduced well-being and loss of productivity were contributors to the high economic burden in patients with late-stage age-related macular degeneration (AMD) living in the US, Germany, and Bulgaria.
Karyopharm (NASDAQ:KPTI) traded higher on Thursday after the company said, based on feedback from the FDA, it has redesigned its Phase 3 SENTRY Trial for its lead asset selinexor in patients with ...